Upcoming Earnings Schedule, Supply and Collaboration Agreements, Financial Results, and Stock Options - Research Report on

  Upcoming Earnings Schedule, Supply and Collaboration Agreements, Financial
     Results, and Stock Options - Research Report on Natus, Haemonetics,
                 AngioDynamics, Horizon Pharma, and ImmunoGen

Editor Note: For more information about this release, please scroll to bottom.

PR Newswire

NEW YORK, January 15, 2014

NEW YORK, January 15, 2014 /PRNewswire/ --

Today, Analysts' Corner announced new research reports highlighting Natus
Medical, Inc. (NASDAQ: BABY), Haemonetics Corporation (NYSE: HAE),
AngioDynamics, Inc. (NASDAQ: ANGO), Horizon Pharma, Inc. (NASDAQ: HZNP), and
ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free
of charge - including full price targets, industry analysis and analyst
ratings - via the links below.

Natus Medical, Inc. Research Report

On January 8, 2014, Natus Medical, Inc. (Natus) announced that it will release
its Q4 2013 financial results on January 29, 2014, before the market opens.
The Company stated that its management will host an investment-community
conference call on the same day at 8:00 a.m. PT / 11:00 a.m. ET to discuss the
results, as well as to answer questions. Natus added that the call can be
accessed through its website, where a recording of the call will be available
for 90 days after the call concludes. The Full Research Report on Natus
Medical, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/03ac_BABY 

--

Haemonetics Corporation Research Report

On January 12, 2014, Haemonetics Corporation (Haemonetics) announced that it
has entered into a multi-year agreement with HemeXcel Purchasing Alliance LLC
(HemeXcel) to supply HemeXcel with certain whole blood collection components
on an exclusive basis during 2014-2016. Brian Concannon, Haemonetics'
President and CEO, commented, "We are very pleased with our selection by
HemeXcel to meet their needs for whole blood collection products. We
appreciate their confidence in our ability to deliver high quality products
and services economically." Haemonetics added that the incremental business
volume is not expected to have a material impact on its FY 2014 revenue or
earnings. According to the Company, the incremental volume will represent
approximately five net points of US whole blood disposables share gain in FY
2015 and beyond, considered together with a smaller recent U.S. tender that
was not awarded to the Company. Haemonetics informed that a live webcast
presentation will be held at 10:00 a.m. PT / 1:00 p.m. ET on January 15, 2014
to comment on this agreement. The Full Research Report on Haemonetics
Corporation - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/7c61_HAE

--

AngioDynamics, Inc. Research Report

On January 9, 2014, AngioDynamics, Inc. (AngioDynamics) reported financial
results for Q2 FY 2014 (period ended November 30, 2013). In Q2 FY 2014, the
Company's net sales increased 1.8% YoY to $88.6 million, while net loss for
the quarter was c.$0.1 million, or break-even on a per share basis, compared
to net income of c.$2 million, or $0.06 per diluted share, in Q2 FY 2013.
Joseph M. DeVivo, President and CEO of AngioDynamics, commented,
"AngioDynamics' better than expected sales reflects improved performance in
our three businesses - Peripheral Vascular, Vascular Access and
Oncology/Surgery - compared to the prior quarter. Our new products,
specifically AngioVac, BioFlo PICCs and ports, and the Acculis microwave
system, represent disruptive emerging technologies that are contributing to
our growth while improving patient outcomes and reducing costs to the
healthcare system." Mark Frost, Executive Vice President and CFO, added, "We
are anticipating revenue to range from $85 million to $88 million in the
fiscal third quarter of 2014, a 4% to 8% increase at the top end compared with
the year ago fiscal third quarter. Adjusted EPS, excluding amortization, is
expected to be $0.15 to $0.18 per share." The Full Research Report on
AngioDynamics, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/3fa9_ANGO

--

Horizon Pharma, Inc. Research Report

On January 9, 2014, Horizon Pharma, Inc. (Horizon Pharma) announced that the
Compensation Committee of the Company's Board of Directors has approved the
grant of inducement stock options to purchase an aggregate of 363,900 shares
of common stock to 93 new employees, in accordance with the NASDAQ Listing
Rule 5635(c)(4). The Company informed that each stock option has an exercise
price per share of $8.59, vests over four years, has a ten year term, and is
subject to the terms and conditions of the Company's 2011 Equity Incentive
Plan and the stock option agreement. The Full Research Report on Horizon
Pharma, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/05ea_HZNP

--

ImmunoGen, Inc. Research Report

On January 9, 2014, ImmunoGen, Inc. (ImmunoGen) announced a multi-year,
strategic collaboration with CytomX Therapeutics (CytomX) to develop
Probody-drug conjugate (PDC) therapies for the treatment of cancer. ImmunoGen
informed that under the agreement, the Companies will collaborate to develop
PDCs against a defined number of targets, bringing together CytomX's
proprietary antibody masking technology and tumor-selective protease
substrates with ImmunoGen's antibody-drug conjugate (ADC) cell-killing agents
and engineered linkers. John Lambert, PhD, Executive Vice President and Chief
Scientific Officer of ImmunoGen, commented, "We believe using our
state-of-the-art ADC technology with CytomX's highly promising Probody
Platform will enable us to develop therapies particularly well-suited for
certain challenging cancers." The Full Research Report on ImmunoGen, Inc. -
including full detailed breakdown, analyst ratings and price targets - is
available to download free of charge at:

http://www.analystscorner.com/r/full_research_report/11c8_IMGN

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by Nidhi Vatsal, a CFA charterholder. However, we are
    only human and are prone to make mistakes. If you notice any errors or
    omissions, please notify us below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquiries, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider represented by Nidhi Vatsal, CFA, has
only reviewed the information provided by Equity News Network in this article
or report according to the Procedures outlined by Equity News Network. Equity
News Network is not entitled to veto or interfere in the application of such
procedures by the outsourced provider to the articles, documents or reports,
as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA
Institute.

AnalystsCorner.com

SOURCE Analysts' Corner

Contact: Joe Thomas, CONTACT PHONE: +1-310-496-8071 (North America)
 
Press spacebar to pause and continue. Press esc to stop.